• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依那普利降压治疗对淀粉样血管病相关脑出血的影响:PROGRESS 试验。

Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.

机构信息

The George Institute for International Health, University of Sydney and the Royal Prince Alfred Hospital, Sydney, Australia.

出版信息

Stroke. 2010 Feb;41(2):394-6. doi: 10.1161/STROKEAHA.109.563932. Epub 2009 Dec 31.

DOI:10.1161/STROKEAHA.109.563932
PMID:20044530
Abstract

BACKGROUND AND PURPOSE

Patients with cerebral amyloid angiopathy (CAA) are at high risk for intracerebral hemorrhage (ICH), but no effective prevention strategies have been established. The objective is to determine whether lowering of blood pressure (BP) provides protection for this high-risk patient group.

METHODS

This study is a subsidiary analysis of the PROGRESS trial-a randomized, placebo-controlled trial that established the beneficial effects of BP lowering in patients with cerebrovascular disease; 6105 patients were randomly assigned to either active treatment (perindopril for all participants plus indapamide for those with neither an indication for nor a contraindication to a diuretic) or matching placebo. Outcomes were probable CAA-related ICH as defined by the Boston criteria, probable hypertension-related ICH, and unclassified ICH.

RESULTS

Over a mean follow-up of 3.9 years, 16 probable CAA-related ICH, 51 probable hypertension-related ICH, and 44 unclassified ICH occurred. Active treatment reduced the risk of CAA-related ICH by 77% (95% CI, 19%-93%), that of hypertension-related ICH by 46% (95% CI, 4%-69%), and that of unclassified ICH by 43% (95% CI, -5%-69%). There was no evidence of differences in the magnitude of the effects of treatment among different types of ICH (P homogeneity=0.4).

CONCLUSIONS

BP-lowering treatment is likely to provide protection against all types of ICH.

摘要

背景与目的

脑淀粉样血管病(CAA)患者发生脑出血(ICH)的风险较高,但尚未建立有效的预防策略。本研究旨在确定降压治疗是否可为这一高危患者群体提供保护。

方法

本研究是 PROGRESS 试验的一项亚组分析,该试验是一项随机、安慰剂对照试验,证明了降压治疗对脑血管病患者有益。6105 例患者被随机分为积极治疗组(所有患者接受培哚普利治疗,无利尿剂适应证或禁忌证者加用吲达帕胺)或匹配安慰剂组。主要转归为波士顿标准定义的可能与 CAA 相关的 ICH、可能与高血压相关的 ICH 和未分类 ICH。

结果

平均随访 3.9 年期间,发生了 16 例可能与 CAA 相关的 ICH、51 例可能与高血压相关的 ICH 和 44 例未分类 ICH。积极治疗使 CAA 相关 ICH 的风险降低了 77%(95%CI,19%-93%),高血压相关 ICH 的风险降低了 46%(95%CI,4%-69%),未分类 ICH 的风险降低了 43%(95%CI,-5%-69%)。不同类型 ICH 之间治疗效果的差异无统计学意义(P 同质性=0.4)。

结论

降压治疗可能为所有类型的 ICH 提供保护。

相似文献

1
Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.依那普利降压治疗对淀粉样血管病相关脑出血的影响:PROGRESS 试验。
Stroke. 2010 Feb;41(2):394-6. doi: 10.1161/STROKEAHA.109.563932. Epub 2009 Dec 31.
2
Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.根据中风亚型和病史,培哚普利降压方案对复发性中风风险的影响:PROGRESS试验
Stroke. 2004 Jan;35(1):116-21. doi: 10.1161/01.STR.0000106480.76217.6F. Epub 2003 Dec 11.
3
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.培哚普利降压可降低心房颤动合并既往卒中或短暂性脑缺血发作患者的主要血管事件风险。
Stroke. 2005 Oct;36(10):2164-9. doi: 10.1161/01.STR.0000181115.59173.42. Epub 2005 Sep 1.
4
Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial.依那普利保护复发性卒中研究(PROGRESS)试验:降压治疗对单纯舒张期高血压患者主要血管事件的影响。
Stroke. 2011 Aug;42(8):2339-41. doi: 10.1161/STROKEAHA.110.606764. Epub 2011 Jun 23.
5
Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients.脑淀粉样血管病在高血压患者脑出血中的作用。
Neurology. 2005 Apr 12;64(7):1233-7. doi: 10.1212/01.WNL.0000156522.93403.C3.
6
Primary Intracerebral Hemorrhage: A Closer Look at Hypertension and Cerebral Amyloid Angiopathy.原发性脑出血:高血压与脑淀粉样血管病的深入探讨。
Neurocrit Care. 2018 Aug;29(1):77-83. doi: 10.1007/s12028-018-0514-z.
7
Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease.脑血管疾病患者中低密度脂蛋白颗粒与脑出血风险
Eur J Cardiovasc Prev Rehabil. 2007 Jun;14(3):413-8. doi: 10.1097/HJR.0b013e328010f275.
8
Risk of Intracerebral Hemorrhage and Mortality After Convexity Subarachnoid Hemorrhage in Cerebral Amyloid Angiopathy.脑淀粉样血管病凸面蛛网膜下腔出血后发生脑出血和死亡的风险。
Stroke. 2019 Sep;50(9):2562-2564. doi: 10.1161/STROKEAHA.119.026244. Epub 2019 Jul 24.
9
Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial.在PROGRESS试验中,既往事件可预测脑血管和冠状动脉结局。
Stroke. 2006 Jun;37(6):1497-502. doi: 10.1161/01.STR.0000221212.36860.c9. Epub 2006 Apr 20.
10
Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage.散发性脑淀粉样血管病并非自发性脑出血的常见病因。
Eur J Neurol. 2007 Aug;14(8):923-8. doi: 10.1111/j.1468-1331.2007.01880.x.

引用本文的文献

1
Importance of blood pressure lowering in patients with direct oral anticoagulant-associated intracerebral haemorrhage in the acute phase and for secondary prevention.直接口服抗凝剂相关脑出血急性期患者血压降低及二级预防的重要性
Eur Stroke J. 2025 Apr;10(1_suppl):46-55. doi: 10.1177/23969873231208544. Epub 2025 May 22.
2
Oral Anticoagulation following intracranial haemorrhage in patients with atrial fibrillation.心房颤动患者颅内出血后的口服抗凝治疗。
Eur Stroke J. 2025 Apr;10(1_suppl):35-45. doi: 10.1177/23969873241296803. Epub 2025 May 22.
3
Hereditary Haemorrhagic Cerebrovascular Disease: Implications for Clinical Management.
遗传性出血性脑血管病:对临床管理的启示
Ann Neurosci. 2025 Mar 18:09727531241308346. doi: 10.1177/09727531241308346.
4
Antihypertensive Medication Class and Functional Outcomes After Nonlobar Intracerebral Hemorrhage.非叶性脑出血后的降压药物类别与功能转归
JAMA Netw Open. 2025 Feb 3;8(2):e2457770. doi: 10.1001/jamanetworkopen.2024.57770.
5
Deciphering the role of APOE in cerebral amyloid angiopathy: from genetic insights to therapeutic horizons.解读载脂蛋白E在脑淀粉样血管病中的作用:从遗传学见解到治疗前景
Ann Med. 2025 Dec;57(1):2445194. doi: 10.1080/07853890.2024.2445194. Epub 2025 Jan 2.
6
Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine.脑淀粉样血管病与心房颤动的管理:我们距离精准医学仍有很大差距。
World J Cardiol. 2024 May 26;16(5):231-239. doi: 10.4330/wjc.v16.i5.231.
7
Clinical characteristics of cerebral amyloid angiopathy and risk factors of cerebral amyloid angiopathy related intracerebral hemorrhage.脑淀粉样血管病的临床特征及脑淀粉样血管病相关性脑出血的危险因素
J Neurol. 2024 Aug;271(8):5025-5034. doi: 10.1007/s00415-024-12451-9. Epub 2024 May 26.
8
Hypertension control after intracerebral hemorrhage among varying small vessel disease etiologies.不同小血管病病因的脑出血后的血压控制
Neurol Sci. 2024 Oct;45(10):4913-4921. doi: 10.1007/s10072-024-07560-2. Epub 2024 May 21.
9
Risk factors for intracerebral hemorrhage in small-vessel disease and non-small-vessel disease etiologies-an observational proof-of-concept study.小血管疾病和非小血管疾病病因所致脑出血的危险因素——一项观察性概念验证研究
Front Neurol. 2024 Mar 7;15:1322442. doi: 10.3389/fneur.2024.1322442. eCollection 2024.
10
Vascular smooth muscle cell-specific Igf1r deficiency exacerbates the development of hypertension-induced cerebral microhemorrhages and gait defects.血管平滑肌细胞特异性 Igf1r 缺陷加重高血压诱导的脑微出血和步态缺陷的发展。
Geroscience. 2024 Jun;46(3):3481-3501. doi: 10.1007/s11357-024-01090-7. Epub 2024 Feb 23.